Alembic Pharmaceuticals has receivedapproval from the US Food & Drug Administration (USFDA) for its Abbreviated NewDrug Application (ANDA) Bimatoprost Ophthalmic Solution, 0.03%. The approvedANDA is therapeutically equivalent to the reference listed drug (RLD), Lumigan, 0.03%of Allergan Sales, LLC (Allergan). Bimatoprost Ophthalmic Solution, 0.03% isindicated for the reduction of elevated intraocular pressure in patients with open angleglaucoma or ocular hypertension.

Bimatoprost Ophthalmic Solution, 0.03% have an estimated market size of US$ 76million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 90 ANDA approvals (78 final approvals and 12 tentativeapprovals) from USFDA.


0 thoughts on “Alembic Pharmaceuticals receives USFDA approval for ANDA Bimatoprost Ophthalmic Solution”

Post Comment

  SureShot Intraday Performance

Sure Shot Intraday performance will be given usually at any time of the trading day whenever the trend occurs in market.

View My Stats